Trial compares effectiveness of Fosamax, Actonel

09/28/2004 | Wall Street Journal, The

Merck's Fosamax and Procter & Gamble's Actonel stop bone deterioration and increase density, but the firms differ on the importance of density in predicting whether bones will or will not break as easily as without the drugs. The Wall Street Journal reports Merck is expected to announce trial results this week that analysts predict will show Fosamax increases bone density more than Actonel. P&G markets Actonel in cooperation with Aventis and insists increased bone density does not necessarily reduce the risk of fractures.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Medical Director - Physician
Willamette Valley Community Health
Salem, OR